CAS: 6082-66-2; 3,4,6-Trichloropyridazine

相似化合物

20074-67-3 14161-11-6 1677-80-1

上下游产品

4-chloro-1,2-dihydro-pyridazine-3,6-dione 4-bromo-1,2-dihydropyridazine-3,6-dione 3,6-dichlorpyridazine pyridazine-3,4,6-triol 4,6-dichloro-2,3-dihydropyridazin-3-one 5,6-dichloro-2,3-dihydropyridazin-3-one H-pyridazin-4-one3,6-dichloro-1H-pyridazin-4-one 3,6-dichloropyridazin-4-amine

溴代马来酸酐置于肼,三氯氧磷体系中,用 水 作为反应溶剂,化学反应 7.5H,以87%的收率获得产物3,4,6-三氯哒嗪
参考文献:作为细菌iia型拓扑异构酶的有效抑制剂的新型三环类化合物(例如,Gsk945237)
标题:作为细菌iia型拓扑异构酶的有效抑制剂的新型三环类化合物(例如,Gsk945237)
摘要:在我们对nbti(新型ii型细菌拓扑异构酶抑制剂)抗菌剂的前导优化研究过程中,我们发现了一系列三环化合物,它们均显示出非常好的革兰氏阳性和革兰氏阴性效能.在这里,我们将讨论在本系列中研究的各种亚基,并报告对化合物1(gsk945237)的高级研究,该研究证明了非常好的pk和体内功效.
DOI:10.1016/j.Bmcl.2016.03.106

专利信息

专利号:RU-2024517-C1
优先权日:1988-12-06
标 题:Method of synthesis of piperazinylalkyl-3-(2h)-pyridazinones or their pharmaceutically acceptable salts

专利号:WO-2024256496-A1
优先权日:2023-06-14
标题 :[1,2,4]-triazolo[4,3-b]pyridazine derivatives useful as a medicament
发明人：ELIE JONATHAN; GEORGE PASCAL; MIEGE FRÉDÉRIC; MEIJER LAURENT
权利人:PERHA PHARMACEUTICALS
摘要:The present invention relates to a compound of formula (I) or any of its pharmaceutically acceptable salt. The present invention further relates to a synthesis process for manufacturing compound of formula (I) or any of its pharmaceutically acceptable salts, comprising at least a step of reacting a compound of formula (II) with an amine of formula (IV) NHR5R6 for example in a molar ratio ranging from 1 to 20 eq, with respect to the compound of formula (II), in an aprotic solvent or without solvent or else in a protic solvent.

专利号:US-12428395-B2
优先权日:2019-08-01
标题 :Heterocyclic compounds as kinase inhibitor and uses thereof
发明人：PENDHARKAR DHANANJAY; RAMACHANDRAN SREEKANTH A; JADHAVAR PRADEEP S; PANPATIL DAYANAND; SAEED UZMA; KUMAR VIVEK; BIST DIPSHE
权利人:SPEROGENIX THERAPEUTICS LTD
摘要:The present disclosure relates generally to compounds useful in treatment of conditions associated with Checkpoint kinase (CHK), particularly CHK-1 enzymes. Specifically, the present invention discloses compound of formula (IA), which exhibits inhibitory activity against CHK-1 enzymes. Methods of treating conditions associated with excessive activity of CHK-1 enzymes with such compounds is disclosed. Uses thereof, pharmaceutical compositions, kits and method of synthesis also disclosed.

专利号:WO-2022162606-A1
优先权日:2021-01-30
标 题:Heterocyclic compounds as kinase inhibitor and uses thereof
发明人：YAN ZHIYU; WANG XIAOHUI; LIU HANLAN; KHAN PASHA M; PANPATIL DAYANAND; PUJALA BRAHMAM; PENDHARKAR DHANANJAY; JADHAVAR PRADEEP S; SAEED UZMA; KUMAR VIVEK
权利人:SPEROGENIX THERAPEUTICS LTD; INTEGRAL BIOSCIENCES PRIVATE LTD
摘要:The present disclosure relates generally to compounds useful in treatment of conditions associated with Checkpoint kinase (CHK), particularly CHK-1 enzymes. Specifically, the present invention discloses compound of formula (J), which exhibits inhibitory activity against CHK-1 enzymes. Methods of treating conditions associated with excessive activity of CHK-1 enzymes such as cancer, idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH) with such compounds is disclosed. Uses thereof, pharmaceutical compositions, kits and method of synthesis also disclosed. Formula (J)